Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

(MedPage Today) — Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from the VALOR trial and its open…

Source link : https://www.medpagetoday.com/neurology/generalneurology/119165

Author :

Publish date : 2025-12-23 17:46:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

FDA Approves First Oral Medication for Iron Deficiency in Kids

Six-Monthly HIV Prevention Injection Cleared by MHRA

Related Posts

The Midterms Are Coming. Vaccines May Play a Role.

Six-Monthly HIV Prevention Injection Cleared by MHRA

FDA Approves First Oral Medication for Iron Deficiency in Kids

Blood-Based Immune Markers May Predict Response to Preoperative Therapy in TNBC

Reassuring Findings for Use of Common Sleep Medications in Pregnancy

Study Highlights Issues in Care of Latine Patients With HC

The Midterms Are Coming. Vaccines May Play a Role.

Six-Monthly HIV Prevention Injection Cleared by MHRA

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

FDA Approves First Oral Medication for Iron Deficiency in Kids

Blood-Based Immune Markers May Predict Response to Preoperative Therapy in TNBC

Reassuring Findings for Use of Common Sleep Medications in Pregnancy

Study Highlights Issues in Care of Latine Patients With HC

Medicaid Paid More Than $207 Million for Dead People. A New Law Could Help Fix That.

Categories

Archives